Dr. John F. Reilly Of Merck Research Laboratories Boston To Speak At International Business Communications' 11th Annual Drug Discovery Technology & Development World Congress

San Jose, CA - Applied Imaging Corp. announced that Dr. John F. Reilly of Merck Research Laboratories will speak at International Business Communications' 11th Annual Drug Discovery Technology & Development World Congress on August 10, 2006 at the World Trade Center and the Seaport Hotel in Boston, MA.

In his presentation, entitled "Immunohistochemical Biomarkers for Responder Identification," Dr. Reilly will discuss his use of Applied Imaging's Ariol automated imaging and image analysis system in the immunohistochemical analysis of cancer tissue microarrays (TMAs) to identify potential patient populations for new targeted cancer treatments.

"Biomarkers are becoming vital in identifying those patients who are likely to respond to a targeted therapeutic drug regimen," said Dr. Reilly. "The high image quality and advanced image analysis algorithms, coupled with automation, make the Applied Imaging Ariol system a great tool for quantitation of critical biomarkers in cancer patent tissue samples."

"We are delighted that Merck has selected the Ariol automated image analysis system for use in research that Dr. Reilly is conducting" said Robin Stracey, President and CEO of Applied Imaging. "We look forward to his presentation at this year's Drug Discovery Technology & Development World Congress and hope that his discussion will help highlight the growing role for automated systems like our Ariol platform in enhancing speed, accuracy and enriching data in drug research and development efforts."

Dr. Reilly's presentation will take place during the "Biomarkers: Utility, Validation and Applications from Discovery to Clinic" conference session on August 10 at 12:00 p.m. at the World Trade Center and the Seaport Hotel in Boston, MA.

SOURCE: Applied Imaging Corp.